Aixcrypto Holdings Inc (AIXC)

$2.51 -0.02 (-0.79%)
Market Cap 13.06M
Revenue (ttm) 0.00
Net Income (ttm) -6.26M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.01
Volume 52,800
Avg Vol 1,491,920
Day's Range N/A - N/A
Shares Out 5.16M
Stochastic %K 63%
Beta 0.28
Analysts Strong Buy
Price Target N/A

Company Profile

AIxCrypto Holdings, Inc., a clinical-stage therapeutics company, focuses on the development of treatments for adult and pediatric cancer. The company's lead program is QN-302, an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor, which is in Phase I clinical trial for the treatment of pancreatic cancer and other solid tumors. It is also developing Pan-RAS that is in preclinical stage for the treatment of advanced solid tumors. The company was formerly known as...

Industry: Software - Infrastructure
Sector: Technology
Phone: 760 452 8111
Website: qlgntx.com
Address:
5857 Owens Avenue, Suite 300, Carlsbad, United States
intergalactiicSwings
intergalactiicSwings Dec. 13 at 9:39 PM
$AIXC $ILLR $ETHM $RYOJ $IVF cz
1 · Reply
PnLStrikeX_1583
PnLStrikeX_1583 Dec. 12 at 7:19 PM
$AIXC thin AI setup, waiting for a tight base and one heavy volume breakout day
1 · Reply
FaithCap
FaithCap Dec. 12 at 6:35 PM
$AIXC thin AI name on my radar, needs a tight base and one real volume day to become interesting
0 · Reply
CASTMONEY
CASTMONEY Dec. 12 at 2:55 PM
$AIXC $$$ GET READY$$$$$$$
0 · Reply
Awiz2
Awiz2 Dec. 12 at 2:51 PM
$AIXC The next under the radar mover in the AI medical space...ARRXF a true millionaire maker!
0 · Reply
Zurb88
Zurb88 Dec. 12 at 11:15 AM
$AIXC
0 · Reply
Yescando
Yescando Dec. 12 at 9:28 AM
$AIXC why are people watching this ticker?
2 · Reply
CaptivePlants
CaptivePlants Dec. 1 at 10:13 PM
$AIXC Kitty-cat pattern detected. When there is a cat in the chart, the fun is about to start.
5 · Reply
Marypennsylvanialand
Marypennsylvanialand Sep. 30 at 1:50 PM
$AIXC straight up, dookie stock...
0 · Reply
Superbad787
Superbad787 Sep. 11 at 9:34 PM
$AIXC tomorrow 🚀
1 · Reply
Latest News on AIXC
AIxCrypto Rebrands and Begins Trading Under New Ticker AIXC, Advancing Its "Three Driving Forces" Strategy to Become the No.1 Gateway to AI Web3 and a Bridge Between Web2 and Web3

Nov 20, 2025, 12:36 PM EST - 23 days ago

AIxCrypto Rebrands and Begins Trading Under New Ticker AIXC, Advancing Its "Three Driving Forces" Strategy to Become the No.1 Gateway to AI Web3 and a Bridge Between Web2 and Web3

Qualigen Therapeutics Stockholders Approve All Proposals with Majority Vote; Company to Rebrand as AIxCrypto Holdings, Inc. (Nasdaq: AIXC) Following November 20 Nasdaq Ceremony and Announces Transition into AI × Web3 Strategy

Nov 16, 2025, 4:10 PM EST - 27 days ago

Qualigen Therapeutics Stockholders Approve All Proposals with Majority Vote; Company to Rebrand as AIxCrypto Holdings, Inc. (Nasdaq: AIXC) Following November 20 Nasdaq Ceremony and Announces Transition into AI × Web3 Strategy

Qualigen Therapeutics to Rebrand as AIxCrypto After Stockholder Meeting on November 12, with Three Core Goals for 2025

Oct 27, 2025, 11:57 PM EDT - 6 weeks ago

Qualigen Therapeutics to Rebrand as AIxCrypto After Stockholder Meeting on November 12, with Three Core Goals for 2025

Qualigen Therapeutics (QLGN) Stock Soars 62% After-Hours On Partnership With BitGo To Build Multi-Asset Crypto Treasury

Oct 24, 2025, 3:12 AM EDT - 7 weeks ago

Qualigen Therapeutics (QLGN) Stock Soars 62% After-Hours On Partnership With BitGo To Build Multi-Asset Crypto Treasury

BTGO

Qualigen Therapeutics Partners with BitGo to Execute First Multi-Asset C10 Treasury Allocation

Oct 23, 2025, 4:05 PM EDT - 7 weeks ago

Qualigen Therapeutics Partners with BitGo to Execute First Multi-Asset C10 Treasury Allocation

Qualigen Therapeutics Announces the Official Launch of C10 Cryptocurrency Asset Treasury (DAT) Purchases: Why Is This Pullback the Golden Moment CXC10 Has Been Waiting For?

Oct 12, 2025, 9:00 PM EDT - 2 months ago

Qualigen Therapeutics Announces the Official Launch of C10 Cryptocurrency Asset Treasury (DAT) Purchases: Why Is This Pullback the Golden Moment CXC10 Has Been Waiting For?

Qualigen Therapeutics (NASDAQ: QLGN) Announces Executives, Board of Directors Appointments and Auditor Transition

Oct 6, 2025, 7:00 PM EDT - 2 months ago

Qualigen Therapeutics (NASDAQ: QLGN) Announces Executives, Board of Directors Appointments and Auditor Transition

Univest Securities, LLC Announces Closing of $41 Million Strategic Investment in Client Qualigen Therapeutics (NASDAQ: QLGN) from Client Faraday Future (NASDAQ: FFAI)

Sep 30, 2025, 4:00 PM EDT - 2 months ago

Univest Securities, LLC Announces Closing of $41 Million Strategic Investment in Client Qualigen Therapeutics (NASDAQ: QLGN) from Client Faraday Future (NASDAQ: FFAI)

FFAI

Qualigen Therapeutics Announces Successful Closing of $41 Million PIPE Financing Led by Faraday Future, Accelerating New Business Transformation into Crypto

Sep 30, 2025, 7:08 AM EDT - 2 months ago

Qualigen Therapeutics Announces Successful Closing of $41 Million PIPE Financing Led by Faraday Future, Accelerating New Business Transformation into Crypto

Faraday Future Announces Strategic $41 Million Investment in Qualigen Therapeutics, Inc. (NASDAQ: QLGN) f for Crypto Business Through PIPE Transaction

Sep 19, 2025, 6:01 PM EDT - 3 months ago

Faraday Future Announces Strategic $41 Million Investment in Qualigen Therapeutics, Inc. (NASDAQ: QLGN) f for Crypto Business Through PIPE Transaction

Qualigen Therapeutics Announces $4.5 Million Private Placement of Series A-3 Convertible Preferred Stock

Jul 28, 2025, 12:41 PM EDT - 4 months ago

Qualigen Therapeutics Announces $4.5 Million Private Placement of Series A-3 Convertible Preferred Stock

Qualigen Therapeutics, Inc. receives expected notification of deficiency from Nasdaq related to delayed filing of quarterly report on Form 10-Q

May 19, 2025, 5:25 PM EDT - 7 months ago

Qualigen Therapeutics, Inc. receives expected notification of deficiency from Nasdaq related to delayed filing of quarterly report on Form 10-Q

Qualigen Therapeutics, Inc. Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of Annual Report on Form 10-K

May 1, 2025, 4:20 PM EDT - 8 months ago

Qualigen Therapeutics, Inc. Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of Annual Report on Form 10-K

Univest Securities, LLC Announces Successful Closing of $5.1 Million Private Placement for Qualigen Therapeutics, Inc. (NASDAQ: QLGN)

Nov 25, 2024, 5:00 PM EST - 1 year ago

Univest Securities, LLC Announces Successful Closing of $5.1 Million Private Placement for Qualigen Therapeutics, Inc. (NASDAQ: QLGN)

Shares Expected to Begin Trading on Split-Adjusted Basis on November 5, 2024

Nov 1, 2024, 9:00 AM EDT - 1 year ago

Shares Expected to Begin Trading on Split-Adjusted Basis on November 5, 2024

Qualigen Therapeutics, Inc. Announces management changes.

Sep 26, 2024, 5:10 PM EDT - 1 year ago

Qualigen Therapeutics, Inc. Announces management changes.

Qualigen Therapeutics, Inc. Received Extension from Nasdaq Hearings Panel

Sep 20, 2024, 9:00 AM EDT - 1 year ago

Qualigen Therapeutics, Inc. Received Extension from Nasdaq Hearings Panel

Univest Securities, LLC Announces Closing of $3.46 Million Registered Direct Offering for its Client Qualigen Therapeutics, Inc. (NASDAQ: QLGN)

Sep 6, 2024, 5:00 PM EDT - 1 year ago

Univest Securities, LLC Announces Closing of $3.46 Million Registered Direct Offering for its Client Qualigen Therapeutics, Inc. (NASDAQ: QLGN)

Qualigen Therapeutics, Inc. Announces Closing of $3.47 Million Public Offering

Sep 6, 2024, 4:30 PM EDT - 1 year ago

Qualigen Therapeutics, Inc. Announces Closing of $3.47 Million Public Offering

Qualigen Therapeutics, Inc. Announces Pricing of $3.46 Million Public Offering

Sep 5, 2024, 9:00 AM EDT - 1 year ago

Qualigen Therapeutics, Inc. Announces Pricing of $3.46 Million Public Offering

Qualigen Therapeutics, Inc. Received Nasdaq Notice of a Delisting Determination

May 30, 2024, 4:00 PM EDT - 1 year ago

Qualigen Therapeutics, Inc. Received Nasdaq Notice of a Delisting Determination

Qualigen Therapeutics' Novel Direct Pan-RAS Inhibitors Presented at American Association of Cancer Research (AACR) 2024 Annual Meeting

Apr 10, 2024, 8:00 AM EDT - 1 year ago

Qualigen Therapeutics' Novel Direct Pan-RAS Inhibitors Presented at American Association of Cancer Research (AACR) 2024 Annual Meeting

Qualigen Therapeutics Announces Poster Featuring Positive Early Clinical Experience with QN-302, a Novel First-in-Class G-Quadruplex Experimental Anti-Cancer Drug, at the American Association of Cancer Research (AACR) 2024 Annual Meeting

Apr 9, 2024, 8:00 AM EDT - 1 year ago

Qualigen Therapeutics Announces Poster Featuring Positive Early Clinical Experience with QN-302, a Novel First-in-Class G-Quadruplex Experimental Anti-Cancer Drug, at the American Association of Cancer Research (AACR) 2024 Annual Meeting

Qualigen Therapeutics Provides Corporate Update for Third Quarter and To Date 2023

Nov 14, 2023, 4:30 PM EST - 2 years ago

Qualigen Therapeutics Provides Corporate Update for Third Quarter and To Date 2023

Qualigen Therapeutics Announces First Patient Dosed in the Phase 1a Clinical Trial of QN-302 for Treatment of Advanced or Metastatic Solid Tumors

Nov 7, 2023, 8:30 AM EST - 2 years ago

Qualigen Therapeutics Announces First Patient Dosed in the Phase 1a Clinical Trial of QN-302 for Treatment of Advanced or Metastatic Solid Tumors

Poster Highlighting Qualigen Therapeutics' Pan-RAS Inhibitor Platform Presented at AACR Special Conference: Advances in Breast Cancer

Oct 23, 2023, 8:30 AM EDT - 2 years ago

Poster Highlighting Qualigen Therapeutics' Pan-RAS Inhibitor Platform Presented at AACR Special Conference: Advances in Breast Cancer

Qualigen Therapeutics Presents Scientific Data on QN-302 at AACR Special Conference: Pancreatic Cancer 2023

Sep 27, 2023, 8:30 AM EDT - 2 years ago

Qualigen Therapeutics Presents Scientific Data on QN-302 at AACR Special Conference: Pancreatic Cancer 2023

Qualigen Therapeutics Partners with TD2 for Phase 1 Clinical Development of QN-302 for the Treatment of Advanced or Metastatic Solid Tumors

Aug 17, 2023, 8:30 AM EDT - 2 years ago

Qualigen Therapeutics Partners with TD2 for Phase 1 Clinical Development of QN-302 for the Treatment of Advanced or Metastatic Solid Tumors

Qualigen Therapeutics, Inc. Reports Financial Results and Corporate Update for Quarter Ending June 30, 2023

Aug 15, 2023, 8:30 AM EDT - 2 years ago

Qualigen Therapeutics, Inc. Reports Financial Results and Corporate Update for Quarter Ending June 30, 2023

Qualigen Therapeutics Announces US FDA IND Clearance to Initiate Phase 1 Clinical Trial of QN-302 for Treatment of Advanced or Metastatic Solid Tumors

Aug 1, 2023, 8:30 AM EDT - 2 years ago

Qualigen Therapeutics Announces US FDA IND Clearance to Initiate Phase 1 Clinical Trial of QN-302 for Treatment of Advanced or Metastatic Solid Tumors

Qualigen Therapeutics Divests FastPack® Diagnostics Business

Jul 24, 2023, 8:15 AM EDT - 2 years ago

Qualigen Therapeutics Divests FastPack® Diagnostics Business

Poster Highlighting Qualigen Therapeutics' Pan-RAS Inhibitor Platform Presented at American Society of Clinical Oncology (ASCO) 2023 Annual Meeting

Jun 5, 2023, 8:15 AM EDT - 2 years ago

Poster Highlighting Qualigen Therapeutics' Pan-RAS Inhibitor Platform Presented at American Society of Clinical Oncology (ASCO) 2023 Annual Meeting

Qualigen Therapeutics, Inc. Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Corporate Update

May 2, 2023, 4:30 PM EDT - 2 years ago

Qualigen Therapeutics, Inc. Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Corporate Update

Qualigen Therapeutics' Pan-RAS Inhibitor Program Highlighted in Two Abstracts at American Society of Clinical Oncology (ASCO) 2023 Annual Meeting

May 2, 2023, 8:15 AM EDT - 2 years ago

Qualigen Therapeutics' Pan-RAS Inhibitor Program Highlighted in Two Abstracts at American Society of Clinical Oncology (ASCO) 2023 Annual Meeting

Qualigen Therapeutics, Inc. Receives Nasdaq Notice Regarding Delayed Form 10-K Filing

Apr 21, 2023, 5:46 PM EDT - 2 years ago

Qualigen Therapeutics, Inc. Receives Nasdaq Notice Regarding Delayed Form 10-K Filing

Qualigen Therapeutics Announces Four Posters on QN-302 Presented at the American Association of Cancer Research (AACR) 2023 Annual Meeting in Orlando, FL

Apr 18, 2023, 8:45 AM EDT - 2 years ago

Qualigen Therapeutics Announces Four Posters on QN-302 Presented at the American Association of Cancer Research (AACR) 2023 Annual Meeting in Orlando, FL

Qualigen Therapeutics Presents Data On QN-247 in Triple Negative Breast Cancer at the American Association for Cancer Research (AACR) Annual Meeting in Orlando, FL

Apr 18, 2023, 7:30 AM EDT - 2 years ago

Qualigen Therapeutics Presents Data On QN-247 in Triple Negative Breast Cancer at the American Association for Cancer Research (AACR) Annual Meeting in Orlando, FL

Composition of Matter Patent for QN-302 Granted by United States Patent and Trademark Office

Mar 21, 2023, 8:35 AM EDT - 2 years ago

Composition of Matter Patent for QN-302 Granted by United States Patent and Trademark Office

Qualigen Therapeutics to Present Five Posters at the American Association for Cancer Research Annual Meeting 2023

Mar 15, 2023, 9:05 AM EDT - 2 years ago

Qualigen Therapeutics to Present Five Posters at the American Association for Cancer Research Annual Meeting 2023

Qualigen Therapeutics Presents Data on its RAS Inhibitor Program at the American Association for Cancer Research: Targeting RAS Conference

Mar 9, 2023, 8:30 AM EST - 3 years ago

Qualigen Therapeutics Presents Data on its RAS Inhibitor Program at the American Association for Cancer Research: Targeting RAS Conference

Data on Potential Biomarker for Qualigen Therapeutics' Lead Program QN-302 Published in Peer-Reviewed Journal Molecules

Mar 8, 2023, 8:05 AM EST - 3 years ago

Data on Potential Biomarker for Qualigen Therapeutics' Lead Program QN-302 Published in Peer-Reviewed Journal Molecules

Qualigen Therapeutics Chief Executive Officer Michael Poirier Provides Letter to Stockholders

Feb 1, 2023, 9:05 AM EST - 3 years ago

Qualigen Therapeutics Chief Executive Officer Michael Poirier Provides Letter to Stockholders

Qualigen Therapeutics Initiates Good Laboratory Practice (GLP) Toxicology Studies on QN-302

Jan 24, 2023, 9:00 AM EST - 3 years ago

Qualigen Therapeutics Initiates Good Laboratory Practice (GLP) Toxicology Studies on QN-302

Qualigen Therapeutics Promotes Benedict M. Abugan to Vice President, Head of Diagnostics and Corporate Communications

Jan 23, 2023, 9:02 AM EST - 3 years ago

Qualigen Therapeutics Promotes Benedict M. Abugan to Vice President, Head of Diagnostics and Corporate Communications

Qualigen Therapeutics Receives Orphan Drug Designation from the U.S. Food and Drug Administration for QN-302, a G-Quadruplex (G4) Transcription Inhibitor for the Intended Indication of Pancreatic Cancer

Jan 10, 2023, 9:00 AM EST - 3 years ago

Qualigen Therapeutics Receives Orphan Drug Designation from the U.S. Food and Drug Administration for QN-302, a G-Quadruplex (G4) Transcription Inhibitor for the Intended Indication of Pancreatic Cancer

Qualigen Therapeutics Provides Update on Developments at NanoSynex; Significant Progress Reported on Infectious Disease Diagnostic Platform

Jan 5, 2023, 9:00 AM EST - 3 years ago

Qualigen Therapeutics Provides Update on Developments at NanoSynex; Significant Progress Reported on Infectious Disease Diagnostic Platform

Qualigen Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Rule

Dec 12, 2022, 8:30 AM EST - 3 years ago

Qualigen Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Rule

Qualigen Therapeutics Announces Pre-IND Feedback from U.S. Food and Drug Administration Regarding QN-302 for the Treatment of G4-Targeted Advanced Solid Tumors

Dec 7, 2022, 9:10 AM EST - 3 years ago

Qualigen Therapeutics Announces Pre-IND Feedback from U.S. Food and Drug Administration Regarding QN-302 for the Treatment of G4-Targeted Advanced Solid Tumors

Qualigen Therapeutics, Inc. Announces 1-for-10 Reverse Stock Split

Nov 22, 2022, 9:00 AM EST - 3 years ago

Qualigen Therapeutics, Inc. Announces 1-for-10 Reverse Stock Split

Qualigen Therapeutics, Inc. Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Nov 15, 2022, 7:30 AM EST - 3 years ago

Qualigen Therapeutics, Inc. Reports Third Quarter 2022 Financial Results and Provides Corporate Update

intergalactiicSwings
intergalactiicSwings Dec. 13 at 9:39 PM
$AIXC $ILLR $ETHM $RYOJ $IVF cz
1 · Reply
PnLStrikeX_1583
PnLStrikeX_1583 Dec. 12 at 7:19 PM
$AIXC thin AI setup, waiting for a tight base and one heavy volume breakout day
1 · Reply
FaithCap
FaithCap Dec. 12 at 6:35 PM
$AIXC thin AI name on my radar, needs a tight base and one real volume day to become interesting
0 · Reply
CASTMONEY
CASTMONEY Dec. 12 at 2:55 PM
$AIXC $$$ GET READY$$$$$$$
0 · Reply
Awiz2
Awiz2 Dec. 12 at 2:51 PM
$AIXC The next under the radar mover in the AI medical space...ARRXF a true millionaire maker!
0 · Reply
Zurb88
Zurb88 Dec. 12 at 11:15 AM
$AIXC
0 · Reply
Yescando
Yescando Dec. 12 at 9:28 AM
$AIXC why are people watching this ticker?
2 · Reply
CaptivePlants
CaptivePlants Dec. 1 at 10:13 PM
$AIXC Kitty-cat pattern detected. When there is a cat in the chart, the fun is about to start.
5 · Reply
Marypennsylvanialand
Marypennsylvanialand Sep. 30 at 1:50 PM
$AIXC straight up, dookie stock...
0 · Reply
Superbad787
Superbad787 Sep. 11 at 9:34 PM
$AIXC tomorrow 🚀
1 · Reply
terminator71
terminator71 Sep. 11 at 7:26 AM
$AIXC September sometime🚀
1 · Reply
Superbad787
Superbad787 Sep. 10 at 9:59 PM
$AIXC tomorrow 🚀
0 · Reply
HelloAgain123
HelloAgain123 Sep. 10 at 4:35 PM
$AIXC got a phone call asking to vote for r/s i said no on that
4 · Reply
terminator71
terminator71 Sep. 10 at 2:35 PM
$AIXC September sometime🚀
0 · Reply